NJ State Employees Deferred Compensation Plan Takes Position in Medidata Solutions, Inc. (MDSO)
NJ State Employees Deferred Compensation Plan bought a new position in Medidata Solutions, Inc. (NASDAQ:MDSO) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,000 shares of the company’s stock, valued at approximately $390,000.
Other institutional investors have also modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Medidata Solutions in the second quarter worth $601,000. Russell Investments Group Ltd. boosted its position in shares of Medidata Solutions by 80.5% in the second quarter. Russell Investments Group Ltd. now owns 28,574 shares of the company’s stock worth $2,235,000 after buying an additional 12,743 shares during the period. State of Wisconsin Investment Board acquired a new stake in shares of Medidata Solutions in the second quarter worth $7,674,000. LS Investment Advisors LLC boosted its position in shares of Medidata Solutions by 49.5% in the second quarter. LS Investment Advisors LLC now owns 4,947 shares of the company’s stock worth $387,000 after buying an additional 1,637 shares during the period. Finally, Oregon Public Employees Retirement Fund acquired a new stake in shares of Medidata Solutions in the second quarter worth $925,000. 98.49% of the stock is owned by institutional investors and hedge funds.
In other news, COO Michael L. Capone sold 5,000 shares of Medidata Solutions stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $74.53, for a total value of $372,650.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.80% of the company’s stock.
Medidata Solutions, Inc. (MDSO) opened at $71.78 on Friday. The company has a quick ratio of 3.37, a current ratio of 1.29 and a debt-to-equity ratio of 0.61. The firm has a market cap of $4.20 billion, a price-to-earnings ratio of 86.41, a PEG ratio of 4.31 and a beta of 1.78.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The company had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. During the same period last year, the company earned $0.28 earnings per share. The business’s revenue was up 16.7% compared to the same quarter last year. equities analysts forecast that Medidata Solutions, Inc. will post 0.77 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/nj-state-employees-deferred-compensation-plan-takes-position-in-medidata-solutions-inc-mdso/1678184.html.
Several brokerages have recently commented on MDSO. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $80.00 target price on shares of Medidata Solutions in a research report on Friday, October 27th. Dougherty & Co began coverage on Medidata Solutions in a research report on Thursday. They issued a “neutral” rating for the company. Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Thursday. Wells Fargo & Company decreased their target price on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a research report on Friday, October 27th. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $92.00 target price on shares of Medidata Solutions in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $84.25.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.